Sleep Disorders and Kidney Transplant Outcomes: Findings From an 18-Year (1997-2015) Historical Cohort Study

A historic cohort study of kidney transplant recipients with a failed graft was conducted to examine the associations between sleep disorders and kidney transplant outcomes. Adult kidney transplant recipients who were transplanted and failed or died with a functioning graft during the designated study time period (January 1, 1997 to September 1, 2015, inclusive) were included (n=299). The primary independent variables, any sleep disorder and any sleep-disordered breathing disorders, were defined through a diagnosis in a subject’s medical record. Transplant outcomes included: death with a functioning graft, graft survival time, and patient survival time after graft failure. Chi-square statistics were used to compare the proportion of death with a functioning graft between subjects with versus without any sleep disorder and to help inform the censoring approach for graft survival time. Kaplan Meier survival curves were used to examine the relationship of any sleep disorder to survival time. Cox regression models, examined the adjusted relationship of any sleep disorder to the outcomes, graft survival time and patient survival time after graft failure. Sub-analyses also examined associations between sleep-disordered breathing disorders and these outcomes. The prevalence of any sleep disorder in this cohort was 20%, with the majority consisting of sleep apnea diagnoses, a sleep-disordered breathing disorder. Given a statistically significant (p≤0.01, adjusted model) sleep disorder by transplant-year heterogeneity, Cox regression models were stratified by transplant-year for the graft survival outcome. Having a sleep disorder, namely, sleep apnea, was associated with a statistically significantly increased risk of graft failure or cardiovascular related death with a functioning graft among patients transplanted in 2009-2015 (adjusted HR=2.94, p In a single-center cohort of kidney transplant recipients with a failed graft, a sleep apnea diagnosis increased the risk of graft loss nearly three-fold among patients transplanted between 2009-2015. Further research is needed to better understand this relationship and whether prevention strategies, including treating sleep apnea, might increase longevity in kidney transplant patients

An Exploratory Study Examining the Associations between Sunlight Exposure, Sleep Behaviours and Sleep Outcomes during an Arctic Summer

Few evidence-based recommendations exist for maintaining healthy sleep during Arctic summers. Our study aimed to examine associations between sleep hygiene, sunlight exposure and sleep outcomes in workers living in and/or near the Arctic Circle during a 24-h light period. A survey was administered July 2017 to 19 workers at 3 Arctic base camps in Northeastern Alaska. Participants with poorer sleep hygiene reported increased sleepiness (r=.62, p=0.01); this correlation remained moderately strong, albeit not statistically significant (NS), after controlling for shift work (r=.46, p=0.06). No other statistically significant correlations between sleep hygiene and sleep outcomes were found. Weekly daytime (8pm) sunlight exposures, estimated from daily self-reported sunlight exposures for a typical workday and day off, were dichotomised, based on means, into: longer (\u3e45 h/week) versus shorter (/week) daytime exposures, and longer (\u3e16 h/week) versus shorter (/week) evening exposures. Participants reporting longer, versus shorter, weekly daytime sunlight exposure had statistically significantly (Mann-Whitney U=18.00, Z=-1.98, p/=.3 for longer, vis-a-vis shorter, daylight sunlight exposure suggest it could be related to poorer sleep outcomes, such as insufficient sleep and sleep quality, yet, as these correlations were NS, future work is needed to determine this. Weak or no correlations (and NS differences) were found for longer, versus shorter, weekly evening sunlight exposure and sleep outcomes. Findings support previous research suggesting self-regulation behaviours alone are not protective against poor sleep in Arctic environments. Sleep outcomes did not differ statistically significantly by evening sunlight exposure length. Longer weekly daytime sunlight exposure, versus shorter, was significantly associated with decreased sleep duration. Results from this exploratory study should be confirmed in studies using larger sample sizes

Logistical and Analytical Approach to a Failure Aboard the International Space Station

The starboard Solar Alpha Rotary Joint (SARJ) from the International Space Station (ISS) began exhibiting off-nominal electrical demands and vibration. Examination by spacewalking astronauts revealed metallic debris contaminating the system and damage to the outboard race of the SARJ. Samples of the contamination were returned to Earth and analyzed. Excessive friction caused the nitride region of the 15-5 PH stainless steel race to spall, generating the debris and damaging the race surface. Excessive vibration and excess power was required to operate the system as a result

Faecal microbiota in dogs with multicentric lymphoma

Malignant lymphoma B-cell type is the most common canine haematopoietic malignancy. Changes in intestinal microbiota have been implicated in few types of cancer in humans. The aim of this prospective and case-control study was to determine differences in faecal microbiota between healthy control dogs and dogs with multicentric lymphoma. Twelve dogs affected by multicentric, B-cell, stage III-IV lymphoma, and 21 healthy dogs were enrolled in the study. For each dog, faecal samples were analysed by Illumina sequencing of 16S rRNA genes and quantitative PCR (qPCR) for selected bacterial groups. Alpha diversity was significant lower in lymphoma dogs. Principal coordinate analysis plots showed different microbial clustering (P = .001) and linear discriminant analysis effect size revealed 28 differentially abundant bacterial groups in lymphoma and control dogs. The qPCR analysis showed significant lower abundance of Faecalibacterium spp. (q < .001), Fusobacterium spp. (q = .032), and Turicibacter spp. (q = .043) in dogs with lymphoma compared with control dogs. On the contrary, Streptococcus spp. was significantly higher in dogs with lymphoma (q = .041). The dysbiosis index was significantly higher (P < .0001) in dogs with lymphoma. In conclusion, both sequencing and qPCR analyses provided a global overview of faecal microbial communities and showed significant differences in the microbial communities of dogs presenting with multicentric lymphoma compared with healthy control dogs.dog

Tel-eVax: a genetic vaccine targeting telomerase for treatment of canine lymphoma

Background: we have recently shown that Tel-eVax, a genetic vaccine targeting dog telomerase (dTERT) and based on Adenovirus (Ad)/DNA Electro-Gene-Transfer (DNA–EGT) technology can induce strong immune response and increase overall survival (OS) of dogs affected by multicentric Diffuse Large B cell Lymphoma (DLBCL) when combined to COP therapy in a double-arm study. Here, we have utilized a clinically validated device for veterinary electroporation called Vet-ePorator , based on Cliniporator technology currently utilized and approved in Europe for electro- chemotherapy applications and adapted to electrogenetransfer (EGT). Methods: 17 dogs affected by DLBCL were vaccinated using two Ad vector injections (Prime phase) followed by TM DNA–EGT (Boost phase) by means of a Vet-ePorator device and treated in the same time with a 27-week Madison Wisconsin CHOP protocol. The immune response was measured by ELISA assays using pool of peptides. Results: No significant adverse effects were observed. The OS of vaccine/CHOP animals was 64.5 weeks, in line with the previous study. Dogs developed antibodies against the immunizing antigen. Conclusions: Tel-eVax in combination with CHOP is safe and immunogenic in lymphoma canine patients. These data confirm the therapeutic efficacy of dTERT vaccine and hold promise for the treatment of dogs affected by other cancer types. More importantly, our findings may translate to human clinical trials and represent new strategies for cancer treatment

Thermal behaviour of zircon/zirconia-added chemically durable borosilicate porous glass

Macroporous alkali resistant glass has been developed by making additions of zirconia (ZrO2) and zircon (ZrSiO4) to the sodium borosilicate glass system SiO2–B2O3 Na2O. The glass was made using a traditional high temperature fusion process. Differential thermal analysis (DTA) was carried out to identify the glass transition temperature (Tg) and crystallisation temperature (Tx). Based on these findings, controlled heat-treatments were implemented to separate the glass into two-phases; a silica-rich phase, and an alkali-rich borate phase. X-ray diffraction (XRD) was used to identify any crystal phases present in the asquenched and heat-treated glasses. Fourier transform infrared (FTIR) spectroscopy also proved effective in investigating phase separation and crystallisation behaviour. After leaching, a silica-rich skeleton with an interconnected pore structure and a uniform pore distribution was observed. Pore characterisation was carried out using mercury porosimetry. The size and shape of the pores largely depended on the heattreatment temperature and time. ZrO2/ZrSiO4 additions increased the alkali resistance of the porous glass 3–4 times

Prevalence of Dal blood type and dog erythrocyte antigens (DEA) 1, 4, and 7 in canine blood donors in Italy and Spain

Background: The aim of this study was to determine the prevalence of Dal, and DEA 1, 4, 7 blood types, in a population of canine blood donors from Italy and Spain. Three hundred and twenty blood donor dogs receiving an annual health evaluation were included in the study. DEA 1 blood type was determined using an immunochromatographic strip technique while Dal, DEA 4 and 7 blood types were determined with polyclonal antisera using agglutination on gel columns. Results: Out of 320 dogs blood typed 7 (2 Cane Corso and 5 Doberman Pinschers) (2.2%) were Dal negative; 137 (42.8%) were positive for DEA 1; 320 (100%) were positive for DEA 4 and 43 (13.4%) were positive for DEA 7. Conclusion: This study showed a similar prevalence of DEA 1, 7 and 4 to that reported in previous studies in the same, and in different, geographic areas, and provides new data on the prevalence of the Dal blood group in Italy and Spain. There was no significant difference (P = 0.8409) between prevalence of Dal negative blood types found in our population (2.2%) and the prevalence reported in a canine blood donor population from the USA (2.5%). Our study identified Dal negative dogs in a previously tested breed i.e. Doberman Pinschers, but also the Cane Corso breed was found to have Dal negative dogs

Prevalence of Dal blood type and dog erythrocyte antigens (DEA) 1, 4, and 7 in canine blood donors in Italy and Spain

BackgroundThe aim of this study was to determine the prevalence of Dal, and DEA 1, 4, 7 blood types, in a population of canine blood donors from Italy and Spain. Three hundred and twenty blood donor dogs receiving an annual health evaluation were included in the study. DEA 1 blood type was determined using an immunochromatographic strip technique while Dal, DEA 4 and 7 blood types were determined with polyclonal antisera using agglutination on gel columns.ResultsOut of 320 dogs blood typed 7 (2 Cane Corso and 5 Doberman Pinschers) (2.2%) were Dal negative; 137 (42.8%) were positive for DEA 1; 320 (100%) were positive for DEA 4 and 43 (13.4%) were positive for DEA 7.ConclusionThis study showed a similar prevalence of DEA 1, 7 and 4 to that reported in previous studies in the same, and in different, geographic areas, and provides new data on the prevalence of the Dal blood group in Italy and Spain. There was no significant difference (P=0.8409) between prevalence of Dal negative blood types found in our population (2.2%) and the prevalence reported in a canine blood donor population from the USA (2.5%). Our study identified Dal negative dogs in a previously tested breed i.e. Doberman Pinschers, but also the Cane Corso breed was found to have Dal negative dogs

Guida pratica alla trasfusione di sangue nel cane

La trasfusione di sangue è una procedura che consente il trasferimento di sangue (o com- ponenti o derivati) da un soggetto donatore sano a un soggetto ricevente. È considerata una sorta di trapianto e per questo è poten- zialmente soggetta a rischio di incompatibili- tà (cd. reazioni trasfusionali). In Italia la trasfusione di sangue intero nel cane è regolata dalla “Linea Guida relativa all’e- sercizio delle attività sanitarie riguardanti la medicina trasfusionale in campo veterinario” pubblicata sulla GU n. 32 del 7-2-2008, Suppl. Ord. N.32. La presente normativa, purtroppo, non contempla l’impiego di emocomponenti* i quali, a giudizio degli Autori, sono erronea- mente equiparati agli emoderivati** nella nor- mativa riguardante il farmaco veterinario§. L’obiettivo principale è quello di fornire al me- dico veterinario una guida di rapida consul- tazione per l’approccio pratico alla medicina trasfusionale del cane. Il progetto è stato rea- lizzato grazie alla collaborazione tra un gruppo di esperti di questo argomento (costituitosi come Gruppo di Studio Trasfusioni Veterinarie, GSTVet) e Bayer Healthcare-Animal Health che ha fornito il supporto per la pubblicazione di quanto elaborato dagli Autori. Le indicazioni ri- portate nella presente guida sono il frutto della consultazione della bibliografia scientifica in- ternazionale esistente in materia, non disgiunta dall’esperienza dei singoli Autori. Quanto di seguito riportato vuole rappresen- tare solo l’inizio di un percorso di aggiorna- mento più ampio che prevede di trattare nel prossimo futuro anche l’impiego degli emo- componenti e degli emoderivati, al momento non ancora disponibili in Italia per l’attività del medico veterinario. In questa prima parte sono illustrate la scelta e la gestione del cane donatore di sangue, le modalità della raccolta del sangue, la gestio- ne della sacca di sangue intero e le indicazio- ni terapeutiche della trasfusione di sangue intero, inclusa la gestione dell’emotrasfusio- ne. Questo articolato processo richiede la collaborazione di diverse figure professionali che devono: operare in sinergia al fine di tu- telare la salute e il benessere del donatore e del ricevente; offrire al ricevente il miglior in- tervento terapeutico possibile, fornendo un prodotto sicuro di elevata qualità sanitaria; ottimizzare l’utilizzo del sangue, prodotto di elevato valore biologico ed etico, di diffici- le reperibilità. Nel testo, volutamente sinte- tico per una sua più agevole consultazione, non sono stati riportati tutti i dettagli propri di una materia così complessa quale la trasfusione